Latest Kura Oncology News & Updates

See the latest news and media coverage for Kura Oncology. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kura Oncology

Precision oncology therapeutics developer

kuraoncology.com

Headquarters: San Diego, United States
Founded year: 2014
Company type: Public company
Number of employees: 300–500

Last updated Today

Latest news about Kura Oncology

In short: Kura Oncology achieved FDA approval for KOMZIFTI and reported strong clinical data for its AML and solid tumor programs through early 2026.

Company announcements

June 11 Kura Oncology

Kura Oncology reports encouraging long-term results for ziftomenib in AML

The Phase 1/2 KOMET-007 trial showed high remission rates and 94% 12-month OS in NPM1-m AML patients.

June 3 Kura Oncology

Kura Oncology highlights darlifarnib as a foundation for KRAS-mutant cancers

Preliminary Phase 1a data show 67% ORR in pancreatic cancer, and a platform study is planned to start in early 2027.

June 2 Kura Oncology

Kura and Kyowa Kirin publish ziftomenib combo data in Blood

The publication reports 87% ORR and 70% CRc in venetoclax-naïve patients with R/R NPM1-m AML.

May 26 Kura Oncology

Kura Oncology reports strong clinical activity with darlifarnib

Combination with adagrasib produced high response rates in PDAC, NSCLC and CRC, including KRASi-experienced patients, with manageable safety.

Media coverage

June 11 Yahoo Finance

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly ...

June 4 The Globe and Mail

Wedbush Sticks to Its Buy Rating for Kura Oncology (KURA)

In a report released today, from Wedbush reiterated a Buy rating on Kura Oncology, with a price target of $36.00. Claim 55% Off TipRanks. Unlock...

June 3 The Globe and Mail

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and...

June 2 Yahoo Finance

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once ...

Never miss news about Kura Oncology

Track Kura Oncology and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kura Oncology competitors & trending companies

Browse news for competitors to Kura Oncology and other trending companies.